Cara Therapeutics Inc (NASDAQ:CARA) – Investment analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for shares of Cara Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. Jefferies Financial Group analyst C. Howerton expects that the biopharmaceutical company will post earnings of ($0.38) per share for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $22.00 target price on the stock. Jefferies Financial Group also issued estimates for Cara Therapeutics’ Q2 2019 earnings at ($0.44) EPS, FY2019 earnings at ($1.94) EPS, FY2020 earnings at ($2.12) EPS, FY2021 earnings at ($1.96) EPS, FY2022 earnings at ($0.13) EPS and FY2023 earnings at $1.19 EPS.
Several other equities analysts also recently weighed in on CARA. Bank of America initiated coverage on Cara Therapeutics in a research note on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 price objective for the company. Laidlaw set a $30.00 target price on Cara Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 20th. Zacks Investment Research upgraded Cara Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research report on Friday, February 8th. HC Wainwright set a $30.00 target price on Cara Therapeutics and gave the company a “buy” rating in a report on Thursday, December 20th. Finally, Janney Montgomery Scott initiated coverage on Cara Therapeutics in a research report on Thursday, December 20th. They issued a “buy” rating and a $13.36 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Cara Therapeutics currently has a consensus rating of “Buy” and an average target price of $24.03.
Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.07. The company had revenue of $5.53 million for the quarter, compared to analyst estimates of $3.35 million.
In related news, CEO Derek T. Chalmers sold 15,825 shares of the company’s stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $12.53, for a total value of $198,287.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Derek T. Chalmers sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 4th. The shares were sold at an average price of $13.61, for a total value of $272,200.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 128,942 shares of company stock valued at $1,871,450. Corporate insiders own 6.70% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. ETF Managers Group LLC purchased a new stake in shares of Cara Therapeutics during the fourth quarter worth about $7,624,000. BlackRock Inc. lifted its stake in shares of Cara Therapeutics by 23.1% during the third quarter. BlackRock Inc. now owns 2,758,118 shares of the biopharmaceutical company’s stock valued at $66,055,000 after buying an additional 516,870 shares during the period. Vanguard Group Inc lifted its stake in shares of Cara Therapeutics by 24.5% during the third quarter. Vanguard Group Inc now owns 1,551,344 shares of the biopharmaceutical company’s stock valued at $37,155,000 after buying an additional 305,020 shares during the period. Vanguard Group Inc. boosted its position in Cara Therapeutics by 24.5% during the third quarter. Vanguard Group Inc. now owns 1,551,344 shares of the biopharmaceutical company’s stock worth $37,155,000 after acquiring an additional 305,020 shares during the last quarter. Finally, Nexthera Capital LP boosted its position in Cara Therapeutics by 69.2% during the third quarter. Nexthera Capital LP now owns 737,303 shares of the biopharmaceutical company’s stock worth $17,658,000 after acquiring an additional 301,503 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.